Touting new way of mining neuro targets, Takeda spinout draws $45M from GV, Bill Gates, Foresite
More than three years after Takeda spun out its top neuroscience team in Cambridge, UK into a transatlantic biotech, GV, Bill Gates and Foresite Capital are chipping in $45 million to power the discovery engine it was founded on.
Cerevance has moved one program — for Parkinson’s — into the clinic; the proceeds should fund others, including several designed to address neuroinflammation in Alzheimer’s disease. With an expected second close of the Series B that should roughly double their take, the biotech should have four more drugs in human trials before they need to raise another round, CEO Brad Margus said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
